GOSSAMER BIO INC

Insider confidence grows as Sandra Milligan exercises a $0 option to buy 10,000 Gossamer Bio shares amid the launch of its pulmonary hypertension drug, hinting at a near‑term upside.

Daniel Thomas O’s insider buy of Gossamer Bio options signals strong confidence ahead of the seralutinib NDA and FDA review, hinting at future upside for investors.